ICH Expansion Prompts WHO To Review Definition Of 'Stringent Regulatory Authorities'
Executive Summary
European research-based pharmaceutical industry association, EFPIA, says it "makes sense" for the World Health Organization to review the concept of "stringent regulatory authorities," which is linked to a country's membership of the International Council for Harmonisation.
You may also be interested in...
WHO Consults On New Framework To Evaluate And List Regulatory Authorities
The new framework, when finalized, will replace the widely-recognized concept of "stringent regulatory authorities."
WHO Regulatory Agency Benchmarking System Set For Early 2019 Launch
The WHO is planning to introduce a new version of its tool for evaluating the “maturity level” of national drug regulatory agencies across the world as part of a drive to strengthen regulatory systems and make them more effective and transparent. It is also introducing the concept of "WHO-listed authority".
WHO Still Planning Biosimilar Naming Guidance, Gives Update On Prequalification Pilot
Despite putting it on hold last year, the World Health Organization is keeping its idea of biosimilar naming guidance alive. And at a recent conference it updated delegates on the pilot project for prequalifying biosimilar versions of infliximab and trastuzumab.